دورية أكاديمية
HIV/AIDS-related lymphoma: perspective from a regional cancer center in India.
| العنوان: | HIV/AIDS-related lymphoma: perspective from a regional cancer center in India. |
|---|---|
| المؤلفون: | Rudresha AH; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Khandare PA; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Lokanatha D; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Linu AJ; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Suresh Babu MC; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Lokesh KN; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Rajeev LK; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Smitha CS; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Amale VB; Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, India., Premalata CS; Department of Pathology, Kidwai Cancer Institute, Bengaluru, India., Nikita M; Department of Pathology, Kidwai Cancer Institute, Bengaluru, India. |
| المصدر: | Blood research [Blood Res] 2019 Sep; Vol. 54 (3), pp. 181-188. Date of Electronic Publication: 2019 Sep 25. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Nature Country of Publication: Korea (South) NLM ID: 101605247 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2287-979X (Print) Linking ISSN: 2287979X NLM ISO Abbreviation: Blood Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2024- : [Cham, Switzerland] : Springer Nature Original Publication: Seoul : Korean Society of Hematology |
| مستخلص: | Background: India has the third largest population of people living with HIV/AIDS (PLHA). Lymphoma is the second most common malignancy among PLHA. However, data are lacking regarding HIV/AIDS-related lymphoma (ARL) in India. This study evaluated the epidemiology and clinical outcomes of ARL from a regional cancer center in India. Methods: This retrospective analysis included cases of ARL between March 2011 and September 2017. Data were obtained from patient record files for the assessment of epidemiology and clinical outcomes. Statistical analysis was performed using GraphPad Prism 6. Comparisons of subtype-specific survivals were performed using log-rank tests. Results: Of 1,226 lymphoma cases, 80 (6.5%) were ARL. Details were available for 70 patients. The median age at diagnosis was 40.5 (9-74) years with a male:female ratio of 2:1. AIDS-defining lymphomas (ADL) constituted 78.6% of cases, while 21.4% had non-AIDS defining lymphoma (NADL). The mean CD4 counts were 193.15±92.85 and 301.93±107.95 cells/µL, respectively (t-test; P =0.0002). Extranodal involvement was present in 55.7%, B symptoms were reported in 60%, and lactate dehydrogenase (LDH) was elevated in 64.3% of patients. The median overall survival times were 6 months for plasmablastic lymphoma (PBL), 23 months for diffuse large B-cell lymphoma (DLBCL), and was not reached for Hodgkin's lymphoma (log-rank test; P =0.0011). Other histological subtype cases were too few to draw meaningful survival outcomes. Conclusion: ARL is a heterogeneous disease. Histologic subtype is a major determinant of the clinical outcome. ADL has significantly lower CD4 counts than those of NADL. There is an urgent and unmet need for uniform management guidelines for improving outcomes in this under-represented patient population. Competing Interests: Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts of interest relevant to this article were reported. (© 2019 Korean Society of Hematology.) |
| References: | N Engl J Med. 1997 Jun 5;336(23):1641-8. (PMID: 9171066) J Natl Cancer Inst. 2013 Aug 21;105(16):1221-9. (PMID: 23892362) JAMA. 1989 Feb 3;261(5):719-24. (PMID: 2536124) Clin Lymphoma. 2003 Sep;4(2):86-92. (PMID: 14556679) J Clin Oncol. 2005 Nov 20;23(33):8477-82. (PMID: 16230675) Curr Opin Oncol. 1997 Sep;9(5):455-64. (PMID: 9327224) Blood. 2003 Jun 15;101(12):4653-9. (PMID: 12609827) Cancer Causes Control. 2008 Mar;19(2):147-53. (PMID: 17992576) MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19. (PMID: 1361652) Blood. 2013 Nov 7;122(19):3251-62. (PMID: 24014242) J Clin Oncol. 2004 Apr 15;22(8):1491-500. (PMID: 15084622) Infect Agent Cancer. 2009 Mar 28;4:4. (PMID: 19327166) AIDS. 2009 Jan 2;23(1):41-50. (PMID: 19050385) Semin Oncol. 1998 Aug;25(4):492-502. (PMID: 9728599) Indian J Cancer. 2014 Oct-Dec;51(4):459-63. (PMID: 26842162) Indian J Cancer. 2018 Jan-Mar;55(1):66-69. (PMID: 30147096) Clin Infect Dis. 2014 Jul 1;59(1):106-14. (PMID: 24642555) HIV Med. 2014 Mar;15 Suppl 2:1-92. (PMID: 24528810) Cancer. 2006 Apr 1;106(7):1560-8. (PMID: 16502436) Blood. 2005 Sep 1;106(5):1538-43. (PMID: 15914552) MMWR Morb Mortal Wkly Rep. 1982 Jun 18;31(23):305-7. (PMID: 6811844) |
| فهرسة مساهمة: | Keywords: AIDS; AIDS-related lymphoma; HIV; Lymphoma |
| تواريخ الأحداث: | Date Created: 20191116 Latest Revision: 20220411 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC6779940 |
| DOI: | 10.5045/br.2019.54.3.181 |
| PMID: | 31730692 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2287-979X |
|---|---|
| DOI: | 10.5045/br.2019.54.3.181 |